Growth Metrics

OptimizeRx (OPRX) EBIT Margin (2016 - 2025)

OptimizeRx (OPRX) has disclosed EBIT Margin for 16 consecutive years, with 26.58% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 1533.0% to 26.58% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 10.69% through Dec 2025, up 2556.0% year-over-year, with the annual reading at 10.69% for FY2025, 2556.0% up from the prior year.
  • EBIT Margin hit 26.58% in Q4 2025 for OptimizeRx, up from 7.86% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 26.58% in Q4 2025 to a low of 54.32% in Q1 2023.
  • Historically, EBIT Margin has averaged 13.64% across 5 years, with a median of 14.78% in 2024.
  • Biggest five-year swings in EBIT Margin: crashed -3404bps in 2023 and later soared 4968bps in 2024.
  • Year by year, EBIT Margin stood at 3.06% in 2021, then crashed by -244bps to 4.4% in 2022, then crashed by -774bps to 38.43% in 2023, then soared by 129bps to 11.25% in 2024, then soared by 136bps to 26.58% in 2025.
  • Business Quant data shows EBIT Margin for OPRX at 26.58% in Q4 2025, 7.86% in Q3 2025, and 10.92% in Q2 2025.